RxDoctor Payments Data

Scott Vargo, MD

Internal Medicine · Pittsburgh, PANPI 1699777573

Payments from drug & device makers

$219in general payments, 2019–2025

Across 13 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$49
  • GSK$44
  • Novo Nordisk$37
  • Stryker$34
  • Merck$17
  • Lilly USA, LLC$14
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$219 in reported general payments places this provider in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$115,588
Medicare patients
319
Services billed
1,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin129$171,070
OzempicSemaglutide128$145,657
EliquisApixaban207$144,555
MounjaroTirzepatide47$50,533
TrulicityDulaglutide37$42,585
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$28,110
MyrbetriqMirabegron40$22,818
MepronAtovaquone11$22,807
XareltoRivaroxaban42$22,342
JanuviaSitagliptin Phosphate40$22,010
Repatha SureclickEvolocumab28$16,740
Breo ElliptaFluticasone/Vilanterol23$14,062
LinzessLinaclotide19$13,777
VascepaIcosapent Ethyl31$12,666
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$12,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$145,657128 claims
PfizerEliquis$49$144,555207 claims
Lilly USA, LLCMounjaro, Trulicity$14$93,11884 claims
GSKTrelegy Ellipta, Mepron, Breo Ellipta, Anoro Ellipta$44$77,31882 claims
MerckJanuvia$17$22,01040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →